Cargando…
Integrated multiomic approach for identification of novel immunotherapeutic targets in AML
BACKGROUND: Immunotherapy of acute myeloid leukemia has experienced considerable advances, however novel target antigens continue to be sought after. To this end, unbiased approaches for surface protein detection are limited and integration with other data types, such as gene expression and somatic...
Autores principales: | Köhnke, Thomas, Liu, Xilong, Haubner, Sascha, Bücklein, Veit, Hänel, Gerulf, Krupka, Christina, Solis-Mezarino, Victor, Herzog, Franz, Subklewe, Marion |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185890/ https://www.ncbi.nlm.nih.gov/pubmed/35681175 http://dx.doi.org/10.1186/s40364-022-00390-4 |
Ejemplares similares
-
Recent developments in immunotherapy of acute myeloid leukemia
por: Lichtenegger, Felix S., et al.
Publicado: (2017) -
Targeting CD157 in AML using a novel, Fc-engineered antibody construct
por: Krupka, Christina, et al.
Publicado: (2017) -
CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023) -
Correction to: CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023) -
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
por: Köhnke, Thomas, et al.
Publicado: (2015)